Iolyx Therapeutics

Iolyx Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Burlingame, California, working at what it calls the intersection of immunology and ophthalmology — "immuno-ophthalmology". The company develops immunomodulatory therapeutics that target ocular inflammation at its source, using what it describes as innovative pathways and tailored formulations for precise delivery to the relevant ocular tissues, positioned as an alternative to conventional steroids and broad immunosuppressants. Its lead asset, ILYX-002, is in trials for autoimmune-associated dry eye disease; the company announced Phase 2 results in May 2025 and, in December 2025, a strategic agreement with Laboratoires Théa to develop and commercialize ILYX-002 alongside Series B funding for its retinal pipeline. The stated pipeline spans front-of-eye indications (dry eye, ocular allergy, rosacea, uveitis) and back-of-eye indications (age-related macular degeneration, diabetic retinopathy, posterior uveitis). Iolyx is a drug developer rather than a software vendor: it operates a six-page WordPress marketing site at iolyx.com and publishes no public API, developer portal, SDK, or machine-readable specification.

Iolyx Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Pharmaceuticals, and Life Sciences.

🌐 Visit website 📡 Source on GitHub

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-25 · rubric v0.14.0

0 APIs

Company Healthcare Biotechnology Pharmaceuticals Life Sciences Ophthalmology Immunology Clinical Trials

Kin Score

Kin Score How this is scored →
scored 2026-08-25 · rubric v0.14.0

Composite quality — 3.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Surface 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/iolyx-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: iolyx-therapeutics
name: Iolyx Therapeutics
description: 'Iolyx Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Burlingame,
  California, working at what it calls the intersection of immunology and ophthalmology — "immuno-ophthalmology". The company
  develops immunomodulatory therapeutics that target ocular inflammation at its source, using what it describes as innovative
  pathways and tailored formulations for precise delivery to the relevant ocular tissues, positioned as an alternative to
  conventional steroids and broad immunosuppressants. Its lead asset, ILYX-002, is in trials for autoimmune-associated dry
  eye disease; the company announced Phase 2 results in May 2025 and, in December 2025, a strategic agreement with Laboratoires
  Théa to develop and commercialize ILYX-002 alongside Series B funding for its retinal pipeline. The stated pipeline spans
  front-of-eye indications (dry eye, ocular allergy, rosacea, uveitis) and back-of-eye indications (age-related macular degeneration,
  diabetic retinopathy, posterior uveitis). Iolyx is a drug developer rather than a software vendor: it operates a six-page
  WordPress marketing site at iolyx.com and publishes no public API, developer portal, SDK, or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/iolyx-therapeutics/refs/heads/main/apis.yml
image: https://iolyx.com/wp-content/uploads/2023/10/iolyx-logo.png
x-type: company
x-source: harvest:secondary-market
x-harvest-listing: https://www.nasdaqprivatemarket.com/
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Ophthalmology
- Immunology
- Clinical Trials
tags_raw:
- Company
- Health Care
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Ophthalmology
- Immunology
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/iolyx-therapeutics-domain-security.yml
- type: Website
  url: https://iolyx.com/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Iolyx is a clinical-stage drug developer whose entire web presence is a six-page WordPress marketing site (Home,
    Pipeline, Team, News, Media, Contact) with zero blog posts, no developer or API section, no GitHub organization, and no
    package on any public registry — the only machine-readable thing on iolyx.com is the stock WordPress /wp-json/ discovery
    document the hosting stack serves by default, which is not a product API.
  evidence:
  - url: https://iolyx.com/
    status: 200
  - url: https://iolyx.com/openapi.json
    status: 404
  - url: https://iolyx.com/llms.txt
    status: 404
  - url: https://iolyx.com/.well-known/agent-card.json
    status: 404
  - url: https://iolyx.com/wp-json/
    status: 200
  - url: https://api.github.com/orgs/iolyx-therapeutics
    status: 404
  checked: '2026-08-23'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/iolyx-therapeutics"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/iolyx-therapeutics/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/iolyx-therapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.